WEST PHARMACEUTICAL SERVICES INC
For the period ended Jun 30, 2026. Filed Jul 23, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the three months ended June 30, 2026, no director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted orterminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the period covered by this Report, except as follows:
On June 2, 2026, Annette F. Favorite, our Senior Vice President & Chief Human Resources Officer, adopted a Rule 10b5-1 trading arrangement, which is intended to satisfy the affirmative defense of Rule 10b5-1(c). The Rule 10b5-1 trading arrangement provides for the exercise of vested stock options and the sale of up to an aggregate of 15,659 shares of our common stock, subject to the terms and conditions specified in the arrangement. Transactions under the arrangement may occur beginning September 8, 2026 and the arrangement is scheduled to terminate on October 29, 2027, unless earlier terminated in accordance with its terms. Any transactions under the arrangement will be disclosed publicly in filings with the SEC to the extent required by applicable securities laws, rules and regulations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.